EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Differences in the Outcome of Cancer-Associated Thrombosis Depending on Cancer Type

Ramón Lecumberri iD, María Marcos-Jubilar, José Hermida, Pedro Ruiz-Artacho iD

Thrombosis and Haemostasis · 01.11.2025 · 125 (11) · 1053-1059

DOI: 10.1055/a-2535-7400 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.11.2025. Verfasst von Ramón Lecumberri und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Service, Cancer Center Universidad de Navarra, Pamplona, Spain. Hauptthemen laut MEDLINE: Neoplasms, Anticoagulants, Venous Thromboembolism, Thrombosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The outcome of venous thromboembolism in patients with cancer is worse than in patients without cancer, with a higher risk of recurrences, bleeding and death. However, these risks appear to vary depending on the cancer type. While in some tumours the risk of recurrences outweighs the risk of bleeding, in others the risk of major bleeding (MB) during the anticoagulation markedly exceeds the risk of a recurrent event. Balancing these risks could be helpful to tailor the management of cancer-associated thrombosis (CAT) and improve outcomes. In this article, published data from recent randomized clinical trials as well as from some large registries that have reported separated outcomes of CAT depending on cancer type were reviewed. A careful balance of the risk of recurrences and MB events could provide useful insights for clinicians for individualizing treatment strategies in order to improve the outcomes of CAT, as well as for the design of future clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAnticoagulantsVenous ThromboembolismThrombosisVenous ThrombosisHumansHemorrhageTreatment OutcomeRisk FactorsRecurrenceRisk AssessmentRandomized Controlled Trials as Topic

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Hematology Service, Cancer Center Universidad de Navarra, Pamplona, Spain.
  • Internal Medicine Department, Clínica Universidad de Navarra, Madrid, Spain.
  • Consorcio de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.

ORCID-Profile: Ramón Lecumberri, Pedro Ruiz-Artacho

Zitieren

APA

Lecumberri, R., Marcos-Jubilar, M., Hermida, J., & Ruiz-Artacho, P. (2025). Differences in the Outcome of Cancer-Associated Thrombosis Depending on Cancer Type. Thrombosis and Haemostasis, 125(11), 1053-1059. https://doi.org/10.1055/a-2535-7400

Vancouver

Lecumberri R, Marcos-Jubilar M, Hermida J, Ruiz-Artacho P. Differences in the Outcome of Cancer-Associated Thrombosis Depending on Cancer Type. Thrombosis and Haemostasis. 2025;125(11):1053-1059. doi:10.1055/a-2535-7400

BibTeX
@article{Lecumberri2025,
  author = {Lecumberri, Ramón and Marcos-Jubilar, María and Hermida, José and Ruiz-Artacho, Pedro},
  title = {Differences in the Outcome of Cancer-Associated Thrombosis Depending on Cancer Type},
  journal = {Thrombosis and Haemostasis},
  year = {2025},
  volume = {125},
  number = {11},
  pages = {1053--1059},
  doi = {10.1055/a-2535-7400}
}
Kostenlos starten →